Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Magazine

Stalking the Future


J&J lost patent protection on epilepsy and schizophrenia drugs worth $7 billion last year. These new drugs, if cleared by the FDA, could help offset the damage:

YONDELIS

For ovarian cancer

PROMISE: J&J licensed this anti-tumor agent, derived from the sea squirt, and plans to sell it as a combo with its own drug, Doxil

PITFALL: A request by the FDA for more information about the overall survival of clinical trial patients could delay approval

RIVAROXABAN

For preventing blood clots

PROMISE: Developed with Bayer, it could be the first new oral anticoagulant in the U.S. since warfarin hit the market in 1954

PITFALL: The FDA is concerned about side effects such as excessive bleeding and has requested more data

COMFYDE

For epilepsy

PROMISE: It could relieve "partial onset" seizures, the most common and difficult-to-treat type

PITFALL: The FDA asked for more data in August, and research setbacks are limiting the drug's usefulness for other diseases

Data: Company reports


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus